Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S.

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
Indiatimes

Blood sugar rises despite insulin? Here’s why it happens, common causes and ways to prevent

Persistent high blood sugar in diabetes, despite insulin use, often stems from insulin resistance, where cells fail to respond effectively to the hormone. Factors like excess weight, inactivity, ...
Renal & Urology News

Kirsty, an Interchangeable Biosimilar to Novolog, Gets FDA Approval

Kirsty 100units/mL is supplied as a 3mL single-patient-use prefilled pen as well as a 10mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...
Morningstar

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...
Mena FN

Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States

(MENAFN- GlobeNewsWire - Nasdaq) BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully integrated global biosimilars ...
JD Supra

Biocon Regulatory Approval Updates in the U.S. and Europe: Insulin Aspart and Denosumab

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has approved KIRSTY (insulin aspart-xjhz injection), 100 units ...
Medscape

Patient Satisfaction and Costs Associated With Insulin Administered by Pen Device or Syringe During Hospitalization

Study design. This prospective, randomized, controlled, parallel-group study compared the use of pen devices with conventional vials and syringes for the administration of insulin in hospitalized ...
The New England Journal of Medicine

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes

Automated insulin delivery (AID) systems have been shown to be beneficial for patients with type 1 diabetes, but data are needed from randomized, controlled trials regarding their role in the ...
Drug Store News

Biocon Biologics, Civica collaborate to expand insulin Aspart access

Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...
The American Journal of Managed Care

First Insulin Aspart Biosimilar Receives FDA Approval

Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...